Devarbhavi Harshad
Department of Gastroenterology, St. John's Medical College Hospital, Sarjapur Road, Bangalore, India.
J Clin Exp Hepatol. 2012 Sep;2(3):247-59. doi: 10.1016/j.jceh.2012.05.002. Epub 2012 Sep 21.
Idiosyncratic drug-induced liver injury (DILI) is an important cause of morbidity and mortality following drugs taken in therapeutic doses. Hepatotoxicity is a leading cause of attrition in drug development, or withdrawal or restricted use after marketing. No age is exempt although adults and the elderly are at increased risk. DILI spans the entire spectrum ranging from asymptomatic elevation in transaminases to severe disease such as acute hepatitis leading to acute liver failure. The liver specific Roussel Uclaf Causality Assessment Method is the most validated and extensively used for determining the likelihood that an implicated drug caused DILI. Asymptomatic elevation in liver tests must be differentiated from adaptation. Drugs producing DILI have a signature pattern although no single pattern is characteristic. Antimicrobial and central nervous system agents including antiepileptic drugs are the leading causes of DILI worldwide. In the absence of a diagnostic test or a biomarker, the diagnosis rests on the evidence of absence of competing causes such as acute viral hepatitis, autoimmune hepatitis and others. Recent studies show that antituberculosis drugs given for active or latent disease are still a major cause of drug-induced liver injury in India and the West respectively. Presence of jaundice signifies a severe disease and entails a worse outcome. The pathogenesis is unclear and is due to a mix of host, drug metabolite and environmental factors. Research has evolved from incriminating candidate genes to genome wide analysis studies. Immediate cessation of the drug is key to prevent or minimize progressive damage. Treatment is largely supportive. N-acetylcysteine is the antidote for paracetamol toxicity. Carnitine has been tried in valproate injury whereas steroids and ursodeoxycholic acid may be used in DILI associated with hypersensitivity or cholestatic features respectively. This article provides an overview of the epidemiology, the patterns of hepatotoxicity, the pathogenesis and associated risk factors besides its clinical management.
特异质性药物性肝损伤(DILI)是治疗剂量用药后发病和死亡的重要原因。肝毒性是药物研发失败、上市后撤市或限制使用的主要原因。尽管成年人和老年人风险增加,但各年龄段都可能发生。DILI涵盖了从转氨酶无症状升高到严重疾病(如导致急性肝衰竭的急性肝炎)的整个范围。肝脏特异性的鲁塞尔·优克福因果关系评估方法是确定可疑药物导致DILI可能性方面最经过验证且使用最广泛的方法。肝脏检查的无症状升高必须与适应性变化相区分。引起DILI的药物有特征性模式,尽管没有单一模式具有特异性。抗菌药物和包括抗癫痫药在内的中枢神经系统药物是全球DILI的主要原因。在没有诊断测试或生物标志物的情况下,诊断依赖于排除诸如急性病毒性肝炎、自身免疫性肝炎等竞争病因的证据。最近的研究表明,分别在印度和西方国家,用于活动性或潜伏性疾病的抗结核药物仍是药物性肝损伤的主要原因。黄疸的出现意味着病情严重且预后较差。其发病机制尚不清楚,是宿主、药物代谢产物和环境因素共同作用的结果。研究已从确定候选基因发展到全基因组分析研究。立即停用药物是预防或减少进行性损害的关键。治疗主要是支持性的。N-乙酰半胱氨酸是对乙酰氨基酚中毒的解毒剂。肉碱已用于丙戊酸盐损伤的治疗,而类固醇和熊去氧胆酸可能分别用于与超敏反应或胆汁淤积特征相关的DILI。本文除了介绍其临床管理外,还概述了DILI的流行病学、肝毒性模式、发病机制及相关危险因素。